TY - JOUR
T1 - N348i in hiv-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations
AU - Sluis-Cremer, Nicolas
AU - Moore, Katie
AU - Radzio, Jessica
AU - Sonza, Secondo
AU - Tachedjian, Gilda
PY - 2010/1
Y1 - 2010/1
N2 - We previously demonstrated that N348I in HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. However, both of these inhibitors are currently infrequently used in developed countries, and the impact of N348I on newer reverse transcriptase inhibitors, such as tenofovir and etravirine, is unknown. In this study, we demonstrate that N348I alone confers no resistance to tenofovir and low-level resistance to etravirine. However, N348I significantly decreases tenofovir susceptibility when combined with thymidine analogue mutations and etravirine susceptibility when combined with Y181C.
AB - We previously demonstrated that N348I in HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. However, both of these inhibitors are currently infrequently used in developed countries, and the impact of N348I on newer reverse transcriptase inhibitors, such as tenofovir and etravirine, is unknown. In this study, we demonstrate that N348I alone confers no resistance to tenofovir and low-level resistance to etravirine. However, N348I significantly decreases tenofovir susceptibility when combined with thymidine analogue mutations and etravirine susceptibility when combined with Y181C.
UR - http://www.scopus.com/inward/record.url?scp=74249098867&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74249098867&partnerID=8YFLogxK
U2 - 10.1097/QAD.0b013e3283315697
DO - 10.1097/QAD.0b013e3283315697
M3 - Article
C2 - 20010074
AN - SCOPUS:74249098867
SN - 0269-9370
VL - 24
SP - 317
EP - 319
JO - AIDS
JF - AIDS
IS - 2
ER -
